Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 9:1:105-11.
doi: 10.2147/ijwh.s4872.

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

Sa Kingsberg  1 , S Kellogg, M Krychman
Affiliations

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

Sa Kingsberg et al. Int J Womens Health. .

Abstract

Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia resulting from vulvovaginal atrophy will depend on the underlying etiology and might include individualized treatment. A number of forms of vaginal estrogen and manner of delivery are currently available to treat moderate to severe dyspareunia caused by VVA. They all have been shown to be effective and are often the preferred treatment due to the targeted efficacy for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare professionals and patients often find it difficult to broach the subject of sexual problems associated with VVA. However, with minimal effort to initiate a conversation about these problems, healthcare providers can provide useful information to their postmenopausal patients in order to help them each choose the optimal treatment for their needs and symptoms.

Keywords: dyspareunia; postmenopausal vulvovaginal atrophy; vaginal estrogen therapy.

PubMed Disclaimer

References

    1. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3):357–336. - PubMed
    1. Kingsberg SA. Maintaining and evaluating quality of life after menopause. The Female Patient. 1996;(May Suppl)
    1. Utian WH, Janata JW, Kingsberg SA, Patrick LD. Determinants and Quantification of Quality of Life after Menopause: The Utian Menopause Quality of Life Score. In: Aso T, Yamahara T, Fujimoto S, editors. Menopause at the Millenium. Parthenon Publishing; New York: 2000. pp. 00–00.
    1. World Health Organization Education and treatment in human sexuality: the training of health professionals. Report of a WHO meeting; Q Corporation, 49 Sheridan Avenue, Albany, NY 12210. 2000.
    1. Nyirjesy P. Postmenopausal vaginitis. Curr Infect Dis Rep. 2007;9:480–484. - PubMed